DUBLIN and MYSTIC, Conn., Jan. 31, 2011 /PRNewswire/ — Amarin
Corporation plc (Nasdaq:
AMRN), a clinical-stage biopharmaceutical company with a focus
on cardiovascular disease, today issued a special letter to its
shareholders. The text of the letter, written by Joseph S.
Zakrzewski, Executive Chairman and Chief Executive Officer of
Amarin, follows:
Dear Shareholders:
With 2011 now underway, I am pleased to provide you with a brief
review of Amarin’s accomplishments in 2010 and an outline of our
strategy for 2011 and beyond. In summary, 2010 was a very
successful year for us, and we look forward to continued success in
the year to come.
Our Recent Accomplishments Include:
Successful top-line results from our Phase 3 MARINE trial Completed
patient randomization for our Phase 3 ANCHOR trial Strengthened
management team and board of directors Strengthened balance sheet
with additional $100M cash On track for a 2011 NDA submission
AMR101 is Positioned to Be Best-in-Class Therapy for Very
High TriglyceridesIn November 2010, we announced that AMR101,
Amarin’s lead product candidate for the treatment of patients with
very high triglycerides (>500 mg/dL), met the primary endpoint
in the Phase 3 MARINE study with highly significant reductions in
triglycerides from baseline compared to placebo at both the 4 gram
and 2 gram doses. In addition to achieving these key endpoints, the
results of this trial exceeded our expectations with no
statistically significant increase in LDL-cholesterol observed at
either dose, with triglyceride lowering that was greater in the
predefined subset of patients on statin therapy and with
encouraging results regarding prespecified markers of inflammation.
Additionally, we observed in the trial a safety profile for AMR101
similar to placebo. The endpoints for this trial were
establishe
‘/>”/>
